SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it has initiated dosing of patients in its placebo controlled Phase IIa trial for AKP-020, a novel vanadium compound, to test its safety and efficacy in patients with Type 2 Diabetes.
